These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35233571)

  • 1. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
    Abdelnabi R; Foo CS; Zhang X; Lemmens V; Maes P; Slechten B; Raymenants J; André E; Weynand B; Dallmeier K; Neyts J
    Antiviral Res; 2022 Feb; 198():105253. PubMed ID: 35066015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36574296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
    Prakash S; Dhanushkodi NR; Singer M; Quadiri A; Zayou L; Vahed H; Coulon PG; Ibraim IC; Tafoya C; Hitchcock L; Landucci G; Forthal DN; El Babsiri A; Tifrea DF; Figueroa CJ; Nesburn AB; Kuppermann BD; Gil D; Jones TM; Ulmer JB; BenMohamed L
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
    Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
    Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters.
    Armando F; Beythien G; Kaiser FK; Allnoch L; Heydemann L; Rosiak M; Becker S; Gonzalez-Hernandez M; Lamers MM; Haagmans BL; Guilfoyle K; van Amerongen G; Ciurkiewicz M; Osterhaus ADME; Baumgärtner W
    Nat Commun; 2022 Jun; 13(1):3519. PubMed ID: 35725735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
    Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani HH; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
    J Virol; 2023 Sep; 97(9):e0062823. PubMed ID: 37676002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.
    Tanneti NS; Patel AK; Tan LH; Marques AD; Perera RAPM; Sherrill-Mix S; Kelly BJ; Renner DM; Collman RG; Rodino K; Lee C; Bushman FD; Cohen NA; Weiss SR
    mBio; 2024 Apr; 15(4):e0312923. PubMed ID: 38477472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
    Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
    Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
    Nchioua R; Schundner A; Kmiec D; Prelli Bozzo C; Zech F; Koepke L; Graf A; Krebs S; Blum H; Frick M; Sparrer KMJ; Kirchhoff F
    J Virol; 2022 Jun; 96(11):e0059422. PubMed ID: 35543509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.